Clinical Trials

Multiple clinical trials evaluate cangrelor across various cardiovascular conditions, including ST-elevation myocardial infarction, acute coronary syndrome, and coronary artery disease in patients undergoing percutaneous coronary intervention. Spanning Phase 1 through Phase 4 across active, recruiting, completed, terminated, and unknown statuses, these studies are supported by both corporate entities and academic medical centers. Collectively, these investigations assess peri-procedural antiplatelet regimens, switching profiles, high on-treatment platelet reactivity, microvascular obstruction, and acute thrombotic risks.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04667078 RECRUITING
Acute Ischemia
Fondation Ophtalmologique Adolphe de Rothschild
 2022-03-02 PHASE3
NCT07225842 RECRUITING
Coronary Arterial Disease (CAD)
University of Florida
 2026-02-18 PHASE4
NCT06792643 RECRUITING
Cardiogenic Shock; Extracorporeal Membrane Oxygenation Complication; Platelet Dysfunction
IRCCS San Raffaele
 2024-04-01 PHASE2
NCT06089577 RECRUITING
Coronary Artery Disease
Federico II University
 2023-11-01 PHASE4
NCT03551964 COMPLETED
Acute Myocardial Infarction; Cardiogenic Shock
Faculty Hospital Kralovske Vinohrady
 2018-08-01 PHASE4
NCT04927949 COMPLETED
ST-elevation Myocardial Infarction
University Hospital, Caen
 2021-06-08 PHASE4
NCT04668144 COMPLETED
Coronary Artery Disease; Acute Coronary Syndrome
University of Florida
 2021-02-18 PHASE4
NCT03102723 UNKNOWN
STEMI
National Heart Centre Singapore
 2017-10-01 PHASE2
NCT04005729 COMPLETED
Out-Of-Hospital Cardiac Arrest; Acute Coronary Syndrome
University Medical Centre Ljubljana
 2019-07-01 PHASE4
NCT04634162 COMPLETED
Coronary Artery Disease
University of Florida
 2021-02-09 PHASE4
NCT03273075 UNKNOWN
Cardiopulmonary Arrest With Successful Resuscitation; ACS - Acute Coronary Syndrome; Hypothermia, Induced
Medical University of Vienna
 2017-09 PHASE4
NCT03862651 UNKNOWN
Platelet Aggregation Inhibitors
Ospedale Santa Croce-Carle Cuneo
 2019-06-01 PHASE2
NCT02765633 COMPLETED
Partial Obstruction of Systemic to Pulmonary Artery Shunt; Complete Obstruction of Systemic to Pulmonary Artery Shunt
Chiesi Farmaceutici S.p.A.
 2017-01-03 PHASE1
NCT02978040 COMPLETED
Coronary Artery Disease; STEMI - ST Elevation Myocardial Infarction
Insel Gruppe AG, University Hospital Bern
 2017-07-04 PHASE4
NCT03182855 UNKNOWN
Acute Coronary Syndrome; Myocardial Infarction; STEMI - ST Elevation Myocardial Infarction
University of Aarhus
 2018-09-01 PHASE4
NCT03043274 TERMINATED
STEMI - ST Elevation Myocardial Infarction
Khaled Ziada, MD
 2017-01 PHASE4
NCT03247738 COMPLETED
ST Segment Elevation Myocardial Infarction; Percutaneous Coronary Intervention
University of Florida
 2017-11-20 PHASE4
NCT02733341 COMPLETED
Acute Coronary Syndrome (ACS); High On-treatment Platelet Reactivity (HTPR); Microvascular Obstruction (MVO); ST-segment Elevation Myocardial Infarction (STEMI); Thrombolysis in Myocardial Infarction (TIMI); Unstable Angina (UA)
The Royal Wolverhampton Hospitals NHS Trust
 2016-07-21 PHASE4
NCT02943369 COMPLETED
STEMI
Attikon Hospital
 2017-07-28 PHASE4
NCT02081443 COMPLETED
Coronary Artery Disease
University of Florida
 2014-04
NCT01979445 COMPLETED
Coronary Artery Disease (CAD)
The Medicines Company
 2013-12-02 PHASE2
NCT01852019 COMPLETED
Coronary Artery Disease
The Medicines Company
 2013-06 PHASE2
NCT01766466 COMPLETED
Coronary Artery Disease
The Medicines Company
 2013-01 PHASE2
NCT01156571 COMPLETED
Atherosclerosis; Percutaneous Coronary Intervention; Acute Coronary Syndrome
The Medicines Company
 2010-09 PHASE3
NCT00767507 COMPLETED
Acute Coronary Syndrome (ACS)
The Medicines Company
 2008-10 PHASE2
NCT00305162 TERMINATED
Myocardial Infarction (MI); Acute Coronary Syndromes (ACS)
The Medicines Company
 2006-04 PHASE3
NCT00385138 TERMINATED
Atherosclerosis; Acute Coronary Syndrome (ACS)
The Medicines Company
 2006-09 PHASE3
NCT00699504 COMPLETED
Healthy
The Medicines Company
 2008-06 PHASE1
NCT00102674 COMPLETED
Healthy
The Medicines Company
 2005-03 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-03-02)

Check the Cangrelor Tetrasodium product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Cangrelor reversibly binds to the platelet P2Y12 purinergic receptor, thereby blocking adenosine diphosphate-mediated signaling pathways and preventing the downstream activation of the glycoprotein IIb/IIIa complex. This inhibition prevents agonist-induced platelet aggregation and rapid thrombus formation, which provides immediate antiplatelet protection to mitigate acute ischemic complications and myocardial damage in patients undergoing percutaneous coronary intervention or presenting with ST-elevation myocardial infarction.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.